Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy
Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy
Active, not recruiting · NCT06680622 · Registry updated 2026-01-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy | Metastatic Gastro-esophageal Adenocarcinoma | Active, not recruiting | Phase 2 | 2026-01-07 | NCT06680622 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Amgen | 180 |
| Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 34 |
| Johannes Gutenberg University Mainz | 34 |
| Technical University of Munich | 85 |
35 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.